A Double-Blind,Placebo-Controlled Crossover Study Investigating the Effect of Porcine Secretin in Children with Autism

Abstract

Objectives: A recent patient series reported the incidental findings of improved social and language skills in 3 children with autistic spectrum disorders after the administration of secretin, a peptide hormone. However, a subsequent study did not find evidence for a drug effect. Parents are seeking treatment with secretin despite the absence of empirical investigations demonstrating amelioration in autism symptomology. In order to more precisely measure the effects of secretin, this study investigated the effect of a single intravenous dose of porcine secretin on 12 autistic children through a randomized, double-blind, placebo-controlled, crossover study. Children were assessed on objective language and on social, neuropsychological, and gastrointestinal measures to evaluate drug effects. The study was conducted over a 16-week trial. The results indicated that significant differences were not observed on the majority of the dependent variables. Statistically significant differences were observed on measures of positive affect and activity level following secretin infusion. In general, the autistic children did not demonstrate the improvements described in the initial retrospective report.

Get full access to this article

View all access options for this article.

References

1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.

2. Realmutto GM , August FJ , Garfinkel BD . Clinical effect of busprione in autistic children. J Clin Psychopharmacol. 1989;9:122-125.

3. Gordon CT , State RC , Nelson jE , et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441-447.

4. McDougle CJ , Naylor ST , Cohen DJ , et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorders. Arch Gen Psychiatry. 1996;53:1001-1008.

5. Dreiling DA . Pancreatic secretory testing. Gut. 1975;16:653-657.

6. Horvath K , Stefanatos G , Sokolski KN , et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9:9-15.

7. Sandler AD , Sutton KA , DeWeese J , et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341:1801-1806.

8. Lord C , Rutter M , Le Couteur A . Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659-685.

9. Lord C , Rutter M , DiLavore P , Risi S . Autism Diagnostic Observation Schedule-WPS (ADOS-WPS). Los Angeles, CA: Western Psychological Services; 1999.

10.

10. Thorndike RL , Hagen EP , Sattler JM . Stanford-Binet Intelligence Scale, 4th ed. Chicago: Riverside Publishing; 1986.

11.

11. Sparrow S , Balla DA , Cicchetti DV . Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service; 1984.

12.

12. Shapiro E . Minnesota Preschool Affect Rating Scales (MN-PARS). Minneapolis, MN: University of Minnesota; 1997.

13.

13. Shapiro E , McPhee JT , Abbott AA , Sulzbacher SI . Minnesota Preschool Affect Rating Scales: Development, Reliability, and Validity. J Pediatr Psychol. 1994;19:325-345.

14.

14. Wetherby A , Prizant B . Communication and Symbolic Behavior Scales Manual. San Antonio, TX: Special Press; 1990.

15.

15. Miller JF , Chapman RS . Systematic analysis of language transcripts. Madison, WI: Waisman Center of Mental Retardation and Human Development, University of Wisconsin; 1985.

16.

16. Roethlisberger FJ , Dickson WJ . Management and the Worker. Cambridge: Harvard University Press.